Guideline for the Management of Community-Acquired Pneumonia

DEFINITION:
Community-Acquired Pneumonia (CAP) is pneumonia that occurs within 48 hours of hospital admission or is
present on admission to the hospital.

EXECUTIVE SUMMARY: see Appendix A for dosing

Patient not being admitted to the hospital
No comorbidities: Comorbidities present:
• Amoxicillin OR Doxycycline Malignancy, alcoholism, asplenia, diabetes, chronic
heart/lung/liver/renal disease
• Amoxicillin/clavulanate OR cefuroxime PLUS
azithromycin OR doxycycline
• Severe beta-lactam allergy: Fluoroquinolone
(levofloxacin or moxifloxacin)
Patient Admitted to the hospital
Non-Severe: Severe:
• Ampicillin/Sulbactam OR Ceftriaxone PLUS Septic shock, respiratory failure, or 3 minor criteria
Azithromycin OR Doxycycline (preferred) See Box 1 below

• Levofloxacin • Ampicillin/Sulbactam OR Ceftriaxone PLUS

azithromycin* (OR levofloxacin)
• Severe beta-lactam allergy: Levofloxacin

Do not routinely add broad spectrum antibiotics. Evaluate risk factors.

• If history of respiratory tract colonization • Always obtain respiratory tract diagnostic testing
with MRSA, gram-negative rod resistant to and modify therapy based on results
CAP agents, OR recent hospital stay with use • MRSA sputum colonization, post-influenza
of IV antibiotics (>5 days)  Obtain sputum pneumonia, severe necrotizing pneumonia
culture: o Consider addition of vancomycin or
o If culture positive for MRSA consider add linezolid to typical CAP therapy
Vancomycin or Linezolid • Resistant gram-negative sputum colonization
o If culture positive for Pseudomonas (Pseudomonas, organisms resistant to typical CAP
consider use of Piperacillin/tazobactam+ therapy)
OR Cefepime o Consider piperacillin/tazobactam+ PLUS
o Patients improving on typical CAP azithromycin* OR Cefepime PLUS
therapy do not need to have antibiotics Azithromycin*
adjusted • Recent hospital stay with use of IV antibiotics (>5
days)
o Consider addition of vancomycin or
linezolid PLUS
Early transition to oral therapy o Piperacillin/tazobactam+ PLUS
recommended in non-severe CAP azithromycin* OR Cefepime PLUS
Azithromycin*
Duration of Therapy 5 days for Most Patients
*Azithromycin preferred. If azithromycin cannot be used, use levofloxacin. If neither levofloxacin nor azithromycin can be used,
doxycycline can be substituted.
+Avoid use of vancomycin in combination with piperacillin/tazobactam
PURPOSE:

To provide a framework for the initial evaluation and management of adult patient with bacterial causes of CAP
based on recent literature and guidelines. Delays in the initiation of appropriate antibiotic therapy may increase
mortality in severely ill patients, and therapy should not be postponed for the purpose of performing diagnostic
studies in patients who are clinically unstable. In clinically stable patients with diagnostic uncertainty, antibiotics
can be safely withheld while additional work up is underway. Antibiotics should be administered when the
diagnosis is considered likely, preferably while the patient is in the emergency department. Pneumonia order
sets are available within One Chart, which should be utilized to facilitate guideline compliant care. An Infectious
Diseases consult is recommended when dealing with complicated or immunocompromised patients (e.g.,
hematopoietic stem cell or solid organ transplant). Recommendations regarding the management of
immunocompromised pneumonia are provided later in the document (Table 2 and 3).

PATIENT DISPOSITION:
The decision of where to care for a patient with pneumonia should be based on clinical judgment taking into
consideration age, co-morbid conditions, and factors that may compromise the safety of home care and be
supplemented with a clinical decision support tool like the Pneumonia Severity Index (PSI, see Appendix A). The
Pneumonia Severity Index has better discriminatory ability to predict mortality than the CURB-65 scoring
system. Home care is recommended for risk classes I, II, and III. Patients meeting the severe CAP definition
should be admitted to the ICU as they are at high risk for adverse outcomes. Additionally, patients initially
admitted to the ward and subsequently transferred to the ICU have increased mortality compared to those
admitted directly to the ICU.1,2
Severe CAP can be defined by:1,2 Box 1: Minor Criteria of Severe COP (3=ICU)1
1.) Respiratory failure requiring mechanical ventilation OR (1) Respiratory rate ≥ 30 breaths/min
2.) Septic shock with the need for vasopressors OR (2) PaO2/FiO2 < 250
3.) The presence of any three minor criteria (3) Multi-lobar infiltrates
(4) Confusion/disorientation
(5) Uremia (BUN ≥ 20)
(6) Leukopenia (WBC < 4000)
(7) Thrombocytopenia (platelets < 100,000)
(8) Hypothermia (core temperature < 36°C)
(9) Hypotension requiring aggressive fluid
resuscitation.

DIAGNOSTIC TESTING:
All patients thought to have pneumonia should have a chest X-ray and pulse oximetry performed. All admitted
patients should have an assessment of gas exchange (oximetry or arterial blood gas), complete blood cell count
and differential, and complete metabolic panel. Further diagnostic testing should be guided by severity of
illness, location of care, and risk factors for atypical or unusual pathogens.
MICROBIOLOGIC TESTING:
Outpatient CAP: Microbiologic testing is not recommended in patients treated in the outpatient setting unless
they have failed therapy or are being treated with expanded therapy for multi-drug resistant organisms
(MDROs).

Inpatient CAP: A variety of diagnostic tests exist to define the etiology of pneumonia. These should be used
more aggressively in patients with severe pneumonia and those started on broad-spectrum antibiotics targeting
MDROs so therapy can be directed towards appropriate pathogens. Sputum cultures should be utilized
routinely in patients with severe CAP, patients with risk factors for MDRO isolation, immunocompromised
patients, or who have been started on broad-spectrum therapy. Ideally, diagnostic testing should be obtained
before antibiotics are begun, but this is not always possible, and therapy should not be delayed if a sputum
culture cannot be obtained. HIV screening should be considered, especially for patients aged 15-54 years. Use of
the pneumonia panel and COVID-19 testing should be based on current guidance.

Table 1: Diagnostic Testing in CAP

Inpatient CAP (non- Severe CAP Inpatient CAP on Immunocompromised
severe) MDRO Therapy* CAP
Blood Cultures No+ Yes Yes Yes
Sputum Culture or If history of sputum Yes (coupled with Yes Yes
Tracheal Aspirate MRSA or Resistant Pneumonia Panel)
GNR OR recent
hospitalization with IV
antibiotic use >5 days
Urine Antigens No+ If Pneumonia Panel If Pneumonia Panel If Pneumonia Panel not
(Legionella and not obtained not obtained obtained
Pneumococcus)
Respiratory Only if respiratory If Pneumonia Panel Only if respiratory If Pneumonia Panel not
Pathogen Panel virus suspected or to not obtained virus suspected or to obtained
(RPP)** rule out influenza rule out influenza
COVID-19 Testing Yes Yes Yes Yes
Pneumonia No Yes Consider Consider strongly
Panel***
+
Can be considered in select cases where pathogen determination is felt to be important
*See risk factors for MDRO below. Examples of MDRO therapy includes use of anti-MRSA antibiotics and antibiotics active
against P. aeruginosa.
**Pneumonia Panel includes all components of RPP and both should not be used
***See Pneumonia Panel guidance on use

Testing for fungal or mycobacterial pathogens should be considered in patients with presentations suggestive of
these etiologies (cavitation, immunosuppression, etc.) or failure to respond to CAP therapy.
MANAGEMENT:

Antibiotic Selection: The categories of pneumonia have been revised with the elimination of healthcare-
associated pneumonia (HCAP). The HCAP designation resulted in the widespread expansion of broad-spectrum
therapy for pneumonia despite very low rates of isolation of resistant pathogens such as MRSA or P.
aeruginosa.3-5 Additionally, the widespread use of broad-spectrum antibiotics has not been associated with
improved outcomes and may actually be associated with increased mortality.5-7 Current CAP guidelines
recommend using patient risk assessment and individual facility data to determine if therapy for multidrug-
resistant organisms (MDRO) is needed.

Risk Factors for Resistant Pathogens: Colonization with resistant pathogens in CAP is much less likely compared
to HAP/VAP. Most CAP patients should be treated with agents targeting typical respiratory pathogens (beta-
lactam + macrolide). Certain CAP patients are at increased risk of MDRO infection, but management varies
based on the severity of illness. Risk factors for the isolation of resistant pathogens include history of respiratory
colonization with MDROs (MRSA, Pseudomonas, gram negatives resistant to typical CAP agents, etc.) and those
who have recently been hospitalized and been treated with broad spectrum antibiotics for at least 5 days (both
antibiotic and hospital stay required). A history of colonization with resistant pathogens is predictive of
subsequent isolation of this same pathogen. Specific pathogens of concern include MRSA, Pseudomonas, and
other gram-negative rods resistant to typical CAP therapy (both ceftriaxone and levofloxacin). Additionally,
antibiotic therapy, particularly broad-spectrum antibiotics selects for resistance and patients exposed to this,
particularly while in the hospital are at increased risk of pneumonia due to a variety of resistant pathogens
including both MRSA and resistant GNR. Finally, S. aureus, including MRSA, is a cause of post-influenza bacterial
pneumonia and severe cavitary pneumonia.

The management of patients with risk factors for resistance (RFR) varies depending on severity of illness. In
non-severe CAP with RFR the use of empiric, broad-spectrum therapy is NOT recommended. These patients
should have a sputum sample obtained. If a resistant pathogen is detected, therapy could be targeted toward
this organism although if the patient has improved on typical CAP therapy it is reasonable to continue and not
treat the pathogens isolated.

In patients with severe CAP and RFR, it is reasonable to empirically use broad-spectrum therapy. Decisions on
therapy choices should be individualized based on severity of illness and risk factors for resistance. For example,
a patient admitted with non-severe CAP who has a history of MRSA sputum colonization should not be started
on anti-MRSA therapy, but a sputum culture should be obtained. If MRSA is isolated a decision would need to
be made treatment of this pathogen is necessary. Additionally, the presence of risk factors for one resistant
pathogen does not equate to the need for therapy against another. To illustrate, in a patient admitted with
severe CAP with a history of Pseudomonas sputum colonization, it would be reasonable to treat with
piperacillin/tazobactam plus azithromycin, but there is no need for anti-MRSA therapy. Sputum testing should
always be obtained when broad-spectrum therapy is started, and antibiotics narrowed based on the results.
Table 2: Risk Factors for Resistance in CAP
Risk Factors for MRSA Risk factors for resistant Gram- Risk factors for MRSA and
negative rods (Pseudomonas, etc.) resistant Gram-negative rods
- History of MRSA sputum - History of sputum colonization - Recently hospitalized (last 90
colonization (within 1 years) with Pseudomonas or Gram- days) and treated with broad
- Post-influenza pneumonia negative rod resistant to typical spectrum antibiotics for at
- Severe necrotizing pneumonia CAP therapy (within 1 years) least 5 days (both required)

HAP/VAP: Patients who develop pneumonia within the first 5 days of hospitalization should be treated using
the CAP guideline while those who develop pneumonia on day 6+ should be treated as HAP (see NM HAP/VAP
guideline).

Corticosteroids: We recommend against using steroids in patients with pneumonia until more data exists to
support their use. Steroid use in patients with COPD or asthma may be appropriate.

De-escalation: Broad-spectrum empiric antibiotic therapy must be accompanied by a commitment to choose

pathogen-specific therapy once the culture and susceptibility results are known, which is usually within 48-72
hours. Clinical improvement usually becomes apparent after the first 48-72 hours of therapy, and therefore, the
selected antimicrobial regimen should not be changed during this time unless progressive deterioration is noted,
or initial microbiologic studies so dictate. For example, the detection of a specific pathogen on the pneumonia
panel or detection of Legionella via a urine antigen may allow for early adjustments in therapy.

Switch to oral: It is not necessary to start all CAP patients on IV Box 2: Criteria for Clinical Stability:
therapy if they can tolerate oral therapy. However, if the patient • Temperature ≤ 37.8 °C
is being admitted to the ICU, it is recommended that the patient • Heart Rate ≤ 100
receive at least 24 hours of intravenous therapy. Doxycycline, • Respiratory Rate ≤ 24
levofloxacin, and azithromycin have excellent oral bioavailability. • Systolic blood pressure ≥ 90 mm
Patients with CAP may be changed to oral therapy when they are Hg
hemodynamically stable, improving clinically, and able to ingest • Arterial oxygen saturation ≥ 90%
and absorb oral medications. Patients with non-severe or pO2 ≥ 60 mm Hg on room air
pneumonia should be rapidly (within 24 hours) transitioned to
oral therapy if they can tolerate other oral medications.8

Nonresponding pneumonia: Patients who do not improve should be evaluated for noninfectious mimics of
pneumonia, unsuspected or drug-resistant organisms, extra-pulmonary sites of infection, and complications of
pneumonia and its therapy. Diagnostic testing should be directed to whichever of these causes is likely.

Duration of Therapy: Most CAP cases can be treated safely with 5 days of therapy. Duration of therapy may be
individualized and clinicians should consider response to therapy, severity of illness, and possible complications
(empyema, etc.). Generally, patients should be improved and meet the markers of clinical stability (Box 2)
before stopping antibiotics. A recent randomized trial found antibiotics could be safely stopped at 3 days in
patients who met the markers for clinical stability.9 Procalcitonin use can also safely decrease antibiotic
duration and may be utilized to define individual patient durations of therapy that are even shorter than 5 days.
Studies suggest that when PCT values return to normal (< 0.25) or decrease >80% from peak levels it is safe to
stop antibiotics (see discussion below). Those with complications such as abscess, empyema or necrotizing
pneumonia should generally receive longer durations of therapy based on the complication found and the
pathogen isolated (consider Infectious Diseases consultation).

PROCALCITONIN:

Executive Summary: Procalcitonin (PCT) is most useful in situations of diagnostic uncertainty, where bacterial
infection is unclear or alternative diagnoses are possible. Additionally, it can be used to shorten the duration of
therapy, although if short duration of treatment (5 days) is already planned, PCT is unlikely provide additional
benefit. Decisions regarding antimicrobial therapy should NOT be based solely on PCT serum concentrations;
test results should be placed into the clinical context of each patient scenario considering the likelihood of
bacterial infection, the severity of illness, and any other pertinent clinical data. There are non-infectious
conditions which can result in elevated PCT levels (see NM PCT guidance). Finally, if PCT levels will not influence
decision-making, do not order the test.

Procalcitonin (PCT) is the most specific biomarker available diagnosis of systemic bacterial infection and has
been shown to have utility in antibiotic decision making in lower respiratory tract infections (LRTI). Multiple
randomized clinical trials support the use of PCT for assisting clinicians in antibiotic management in LRTI
including pneumonia, exacerbations of chronic bronchitis, and other assorted lower respiratory tract infections
(bronchitis, asthma exacerbation, etc.).10-12 A patient level meta-analysis of 26 trials with 6708 patients found
the use of PCT in LRTI resulted in a significant decrease in mortality (OR 0.83 (95% CI 0.70-0.99, p=.037).13 PCT
use was also associated with a reduction in antibiotic exposure by 2.4 days and decreased antibiotic side effects.
Studies specifically addressing its use in pneumonia have had similar findings of decreased antibiotic use with
equivalent or improved clinical outcomes.10 Although it should be noted that a recent trial where control group
antibiotic duration was very short (mean 4.3 days) did not show benefit from PCT use.14 This suggests that when
short courses of antibiotics are already in use PCT has less utility in shortening duration of therapy.
Procalcitonin is not generally useful in determining the specific microbial etiology of CAP but can be useful in
situations where there diagnostic uncertainty exits regarding the need for antibiotics such as differentiating
pneumonia from heart failure.15,16 Based on this data we continue to recommend PCT use to assist clinicians in
decisions regarding initiation and discontinuation of antimicrobial therapy.

When PCT is used in pneumonia it is recommended it be measured on admission and every 2-3 days
subsequently. Interpretation of PCT values should be as listed below in Algorithms 1 and 2.
Algorithm 1: LRTI Initial PCT Value

Algorithm 2: LRTI PCT Value Follow Up

Community-Acquired Pneumonia (CAP) in Immunocompromised (IC) Patients
Summary: The IDSA-ATS CAP guidelines do not address the management of pneumonia in immunocompromised
patients although this represents a significant proportion of pneumonia patients. In a nationwide epidemiologic
analysis of pneumonia-associated hospitalizations in the US between 2001-2014, the presence of
immunocompromising condition increased from 19% in 2001 to 30% by 2014.17

Data on management of pneumonia in IC patients is scarce and we have summarized information and made
recommendations for initial CAP management in IC adults. Early infectious disease consultation is strongly
encouraged in the IC population due to the likelihood of encountering atypical pathogens.

Definition of Immunocompromise: The definition of immunocompromise varies across studies and pneumonia
etiology may differ based on the IC condition. Various immunosuppressive medications and conditions may
predispose to some pathogens over others and general guidelines on therapeutic choices are provided below.
The list of conditions that are addressed is included below.

• HIV/AIDS, hematologic malignancy, active malignancy receiving chemotherapy, receipt of solid-organ or

hematopoietic cell transplantation, immunosuppressive therapy (including prednisone 0.5 mg/kg/day for at
least 14 days or equivalent), certain autoimmune or rheumatologic conditions, liver or kidney dysfunction,
certain metabolic or endocrinopathies, asplenia (functional or anatomic) and other underlying immune
deficiency (primary immunodeficiency, etc.).

Diagnostic Testing: In general, immunocompromised patients have increased risk factors for atypical, non-CAP
pathogens, and co-infection. Providers should have a lower threshold to obtain diagnostic testing depending on
level of immunosuppression. See Table 1 in CAP Guidance for diagnostic recommendations. In addition, patients
should be assessed for risk of opportunistic infections. Testing for atypical bacteria, Pneumocystis, fungi or
mycobacteria should be considered especially when patients fail to respond to standard CAP therapy.

Antimicrobial Management: Many of the same principles for treating general CAP apply to
immunocompromised CAP. Do not routinely provide broad-spectrum antibiotics (anti-MRSA or anti-
Pseudomonas) but assess patient-specific risk factors for MRSA and Pseudomonas. Seek Infectious Disease (ID)
consultation for suspicion and management of opportunistic or atypical infections. Special attention to drug-
drug interactions and adverse effects in patients with pre-existing organ dysfunction is encouraged.

Table 2: General Guidance for use of Broad-Spectrum Agents in IC CAP:

Indications for MRSA treatment†: Indications for Pseudomonas treatment*:

Generally not indicated. Generally not indicated.
Obtain respiratory tract cultures Obtain respiratory tract cultures
If risk factors present, consider empiric therapy in non- If risk factors present, consider empiric therapy in non-
severe CAP, and add in severe CAP: severe CAP, and add in severe CAP:
- Previous isolation of MRSA in sputum - Previous Pseudomonas in sputum
- Recent hospital stay with IV antibiotics (5 days) - Recent hospital stay with IV antibiotics (5 days)
- Post-influenza or necrotizing pneumonia - Lung transplant
*Cefepime 1g IV q6h OR piperacillin/tazobactam 4.5g IV q8h infused over 4 hours.
†Add Vancomycin (pharmacy to dose) OR linezolid 600 mg IV or PO q12h to typical CAP therapy
Table3: Specific CAP Considerations by Immunocompromised Condition

Immunocompromised- Etiology and Diagnostic Considerations Treatment Considerations

Specific Guideline
HIV • Strep pneumoniae, H. influenzae common. • Per NM CAP guidelines
(AIDS Info guidelines • Assess risk factors for OIs (Pneumocystis, • For concern for OI, consult ID
hyperlinked, p. G-1) TB/NTMs, etc), including co-infection
Solid Organ Transplant Etiology is highly dependent on level of • Anti-MRSA or anti-Pseudomonals
(American Society of immunosuppression and time since transplant. often not needed, evaluate risk
Transplantation ID • Early post-Tx may often have risk factors factors as above
Community of Practice for MRSA and Pseudomonas, later more • Those without risk treat per NM
pneumonia guideline typical organisms CAP guidelines
hyperlinked) • Assess risk factors for OIs (atypical • For concern for OI, consult ID.
bacteria, PJP, endemic & invasive fungi, • Lung transplant recipients:
respiratory viruses) consult Transplant Pulmonology
• Diagnostic work-up is strongly encouraged +/- ID
in consultation with ID
Oncology Etiology is dependent on type & status of • Cancer survivors off
(See National Cancer malignancy, active chemotherapy or immunosuppressive agents, per
Care Network immunotherapies, other immunosuppressive NM CAP guidelines
Guidelines: Prevention agents. • Neutropenic patients: anti-
and Treatment of • Assess risk factors for OIs (atypical Pseudomonal should be included
Cancer Related bacteria, PJP, endemic & invasive fungi, in CAP regimen
Infections) respiratory viruses) • Anti-MRSA agent usually not
• Diagnostic work-up is strongly encouraged needed; base on patient-specific
in consultation with ID risk factors
• For concern for OI, consult ID.
Patients on long-term • At increased risk for microbiologic • Per NM CAP guidelines
corticosteroids etiology not covered by typical • Evaluate need for anti-MRSA and
(prednisone equivalent antimicrobial agents anti-Pseudomonal therapy using
of 0.5 mg/kg/day) ≥2 • Assess patient-specific risk factors for patient risk factors
weeks MRSA, Pseudomonas, respiratory viruses, • For suspected OI, consult ID or
and OIs (PJP, mold, etc) pulmonology
• Diagnostic work-up is encouraged.
Asplenia (functional or • Encapsulated organisms including Strep • Per NM CAP guidelines
anatomic) pneumoniae, H. influenzae are common.
Advanced cirrhosis • Strep pneumoniae is most common • Per NM CAP guidelines
pathogen
Chronic kidney disease • Strep pneumoniae, H. influenzae common • Per NM CAP guidelines

APPENDIX A: Antimicrobial Dosing

Ampicillin/Sulbactam 3g q6h Cefuroxime 500 mg PO q12h

Amoxicillin 1 g PO q8h Doxycycline 100 mg PO/IV q12h
Amoxicillin/clavulanate ER 2 g PO q12h Levofloxacin 750 mg PO/IV daily
Azithromycin 500 mg PO/IV once then 250 mg daily Linezolid 600 mg PO/IV q12h
Aztreonam 2 g IV q8h Piperacillin/tazobactam 4.5 g IV q8h over 4 hours
Cefepime 1 g IV q6h Vancomycin 15 mg/kg IV q12h
Ceftriaxone 2 g IV daily
APPENDIX B: The Pneumonia PORT prediction rule
1. Classify patient into risk class I if they are aged ≤ 50 years, have no neoplastic disease, liver disease,
cerebrovascular disease, renal disease, or congestive heart failure, and have normal or only mildly
abnormal vital signs and normal mental status.
2. Use the tables below to calculate a PORT score for those patients in risk classes II – V and determine site
of care.
______________________________________________________________________________
Patient Characteristic Points assigneda
Demographic factor
Age
Male # of years of age
Female # of years of age - 10
Nursing home resident +10
Comorbid illnesses
Neoplastic diseaseb +30
Liver diseasec +20
Congestive heart failured +10
Cerebrovascular diseasee +10
Renal diseasef +10
Physical examination findings
Altered mental status (disorientation, stupor, or coma) +20
Respiratory rate > 30 breaths/min +20
Systolic blood pressure < 90 mm Hg +20
Temperature < 35°C or > 40°C +15
Pulse > 125 beats/min +10
Laboratory or radiographic findings
Arterial pH < 7.35 +30
Blood urea nitrogen > 30 mg/dL +20
Sodium < 130 mEq/L +20
Glucose > 250 mg/dL +10
Hematocrit < 30% +10
Arterial partial pressure of oxygen < 60 mm Hg g +10
Pleural effusion +10
a A total point score for a given patient is obtained by adding the patient’s age in years (age – 10 for females) and the points for
each applicable patient characteristic.
b Any cancer except basal or squamous cell cancer of the skin that was active at the time of presentation or diagnosed within 1

year of presentation.
c A clinical or histologic diagnosis of cirrhosis or other form of chronic liver disease such as chronic active hepatitis.
d Systolic or diastolic ventricular dysfunction documented by history and physical examination, as well as chest radiography,

echocardiography, Muga scanning, or left ventriculography.

e A clinical diagnosis of stroke, transient ischemic attack, or stroke documented by MRI or computed axial tomography.
f A history of chronic renal disease or abnormal blood urea nitrogen and creatinine values documented in the medical record.
h An oxygen saturation value < 90% on pulse oximetry or intubation before admission is also considered abnormal.

_____________________________________________________________________________________
Risk class # of points Mortality % Recommended site of care_____
I NA 0.1 Outpatient
II ≤ 70 0.6 Outpatient
III 71-90 2.8 Outpatient
IV 91-130 8.2 Inpatient
V > 130 29.2 Inpatient

Revised: Trevor Van Schooneveld, MD, Jasmine Marcelin MD, Erica Stohs MD, Scott Bergman, PharmD (2021)
References
1. Brown SM, Jones JP, Aronsky D, Jones BE, Lanspa MJ, Dean NC. Relationships among initial hospital triage, disease
progression and mortality in community-acquired pneumonia. Respirology 2012;17:1207–1213.
2. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia.
An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of
America. Am J Respir Crit Care Med. 2019;200(7):e45–e67. doi:10.1164/rccm.201908-1581ST
3. Self WH, Wunderink RG, Williams DJ, et al. Staphylcococcus aureus community-acuqired pneumonia: prevalence,
clinical chardacterisitics, and outcomes. Clin Infect Dis. 2016:63:300-9.
4. Jones BE, Jones MM, Huttner B, et al. Trends in antibiotic use and nosocomial pathogens in hospitalized veterans
with pneumonia at 128 medical centers, 2006-2010. Clin Infect Dis. 2015;61:1403-10.
5. Webb BJ, Sorensen J, Jephson A, et al. Broad-spectrum antibiotic use and poor outcomes in community-onset
pneumonia: a cohort study. Eur Respir J. 2019;54:19000057.
6. Kett DH, Cano E, Quartin AA, et al. Implementation of guidelines for management of possible multidrug-resistant
pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis. 2011;11:181-89.
7. Jones BE, Ying J, Stevens V, et al. Empirial anti-MRSA vs standard antibiotic therapy and risk of 30-day mortality in
patients hospitalized for pneumonia. JAMA Int Med. 2020;180:552-60.
8. Ciarkowski CE, Timbrook TT Kukhareva PV, et al. A Pathway for Community-Acquired Pneumonia With Rapid
Conversion to Oral Therapy Improves Health Care Value. Open Forum Infect Dis. 2020;7:ofaa497.
9. Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-
acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo controlled, non-
inferiority trial. Lancet. 2021;397:1195-1203.
10. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired
pneumonia. Am J Respir Crit Care Med. 2006;174:84-93.
11. Schuetz P, Crist-Crain M, Thomann, et al. Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on
Antibiotic Use in Lower Respiratory Tract Infections. JAMA. 2009;302:1059-66.
12. Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and Safety of Procalcitonin-Guided Antibiotic Therapy in
Lower Respiratory Tract Infections in “Real Life.” JAMA Int Med. 2012;172:715-722.
13. Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute
respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18:95-107.
14. Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection.
NEJM. 2018;379:236-249.
15. Self WH, Balk RA, Grijalva CG, et al. Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-
Acquired Pneumonia. Clin Infect Dis. 2017;65:183-90.
16. Schuetz P, Kutz A, Grolimund E, et al. Excluding infection through procalcitonin testing improves outcomes of
congestive heart failure patients presenting with acute respiratory symptoms: Results from the randomized
ProHOSP trial. Int J Cardiol. 2014;175:464-72.
17. Hayes, Haberling DL, Kennedy JL, et al. Burden of Pneumonia-Associated Hospitalizations: United States, 2001-
2014. Chest 2018;153:427-37.